selective COX-2 inhibitor called Prexige

CLICK HERE to view the Health Canada advisory concerning the removal of Prexige from the Canadian market

  You'll soon see a new selective COX-2 inhibitor called Prexige.

  Health Canada approved it ahead of the U.S. and most other countries. It's for acute and chronic osteoarthritis of the knee.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote